Volume 6 Supplement 1

15thPaediatric Rheumatology European Society (PreS) Congress

Open Access

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)

  • A Consolaro1,
  • N Ruperto1,
  • A Bazso1,
  • S Magni-Manzoni2,
  • MA Pelagatti1,
  • A Pistorio1,
  • A Magnani1,
  • C Malattia1,
  • I D'Agostino1,
  • G Filocamo1,
  • A Martini1 and
  • A Ravelli1
Pediatric Rheumatology20086(Suppl 1):P115

https://doi.org/10.1186/1546-0096-6-S1-P115

Published: 15 September 2008

Objective

To complete validation of the Juvenile Arthritis Disease Activity Score.

Materials and methods

The JADAS is composed of the following measures: 1) physician's global assessment (0–10); 2) parent's global assessment (0–10); 3) active joint count (assessed in 71, 27 or 10 joints); 4) ESR (normalized to 0–10). It yields a score ranging from 0 to 40, 57 or 101, depending on whether the whole 71-joint count (JADAS-71) or the 27-joint (JADAS-27) or 10-joint (JADAS-10) reduced counts are used. The 3 versions of the JADAS were tested on juvenile idiopathic arthritis patients included in 2 trials on methotrexate (n = 595) and meloxicam (n = 225). Construct validity was assessed by calculating Spearman's correlation between baseline-endpoint changes in JADAS, C-HAQ and 2 adult scores (DAS28, CDAI). Discriminative validity was assessed by examining the ability of JADAS to discriminate between different levels of ACR Pediatric response in the 2 trials.

Results

Table 1 shows Spearman's correlations on changes in the 2 clinical trials.
Table 1

Spearman's correlations on changes in the 2 clinical trials

 

Methotrexate trial

Meloxicam trial

 

JADAS-71

JADAS-27

JADAS-10

JADAS-71

JADAS-27

JADAS-10

CHAQ

0.46

0.50

0.51

0.44

0.43

0.45

DAS28

0.78

0.80

0.79

0.74

0.74

0.70

CDAI

0.88

0.86

0.72

0.87

0.86

0.75

The JADAS-10 revealed the best discriminative validity, followed by the JADAS-27 and the JADAS-71.

Conclusion

Overall, the JADAS versions including the reduced joint counts (either 27 or 10) revealed better or, at least, similar validity as compared with the version including the 71 (i.e. complete) joint count. Use of JADAS versions with reduced joint counts is advised due to their greater feasibility.

Authors’ Affiliations

(1)
IRCCS G. Gaslini
(2)
IRCCS Policlinico San Matteo

Copyright

© Consolaro et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement